Compare MOS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOS | ERAS |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.3B |
| IPO Year | 2004 | 2021 |
| Metric | MOS | ERAS |
|---|---|---|
| Price | $22.49 | $14.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $25.66 | $24.11 |
| AVG Volume (30 Days) | ★ 10.7M | 4.8M |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ 209.09 | 36.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,052,400,000.00 | N/A |
| Revenue This Year | $0.65 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.36 | N/A |
| 52 Week Low | $16.99 | $2.21 |
| 52 Week High | $32.25 | $24.28 |
| Indicator | MOS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 45.10 |
| Support Level | $20.48 | $13.47 |
| Resistance Level | $24.00 | $15.71 |
| Average True Range (ATR) | 0.89 | 1.07 |
| MACD | 0.70 | -0.03 |
| Stochastic Oscillator | 96.47 | 37.55 |
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in the US and potash mines in Canada. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.